Jinwei Biotechnology

Shanghai Jinwei Biotechnology is a biopharmaceutical company focused on developing innovative therapies for serious infectious diseases and cancers using its proprietary non-integrating lentiviral vector platform. Founded in 2016 and based in Shanghai, the company leverages technology licensed from the Pasteur Institute and TheraVectys to create therapeutic vaccines that elicit potent and sustained T-cell immune responses. Its leading program is a therapeutic vaccine for chronic Hepatitis B, which has demonstrated promising results in investigator-initiated clinical trials. Additionally, Jinwei operates as a CDMO, providing viral vector manufacturing and process development services from its GMP-compliant facility in the Zhangjiang High-tech Park. The company's pipeline also includes neoantigen-based immunotherapies and treatments for HPV-induced malignancies.